March 3, 2020
Consolidated financial results of the Group are reported under U.S. generally accepted accounting principles (“U.S. GAAP”) and in U.S. dollar currency unless otherwise stated. Chi-Med also conducts its business through three non-consolidated joint ventures, which are accounted for under the equity accounting method as non-consolidated entities in our consolidated financial statements. Within this announcement, certain financial results reported by such non-consolidated joint ventures are referred to, which are based on figures reported in their respective consolidated financial statements prepared pursuant to International Financial Reporting Standards (as issued by the International Accounting Standards Board). Unless otherwise indicated, references to “subsidiaries” mean the consolidated subsidiaries and joint ventures (excluding non-consolidated joint ventures) of Chi-Med.
OVERALL GROUP:
INNOVATION PLATFORM:
COMMERCIAL PLATFORM:
(US$ millions) | 2017 | 2018 | 2019 |
---|---|---|---|
Group Consolidated Revenues | 241.2 | 214.1 | 204.9 |
Unconsolidated JV Revenues (excluding divested business Guanbao - Non-GAAP) | 472.0 | 491.5 | 487.5 |
Segment Net (Loss)/Income attributable to Chi-Med | |||
Innovation Platform | (51.9) | (104.4) | (133.2) |
Commercial Platform | 37.5 | 43.4 | 47.4 |
Prescription Drugs Business | 26.5 | 34.1 | 37.5 |
Consumer Health Business | 11.0 | 9.3 | 9.9 |
Group Costs | (14.8) | (13.8) | (20.2) |
Group Net Income/(Loss) attributable to Chi-Med | (26.7) | (74.8) | (106.0) |
EPS Attrib. to Ord. S-H (Basic) (US$) | (0.04) | (0.11) | (0.16) |
For more details, please review our Final Results for the Year Ended December 31, 2019.